Skip to content

Ambrx Biopharma Inc.

CIK 0001836056

← back to feed
Revenue (TTM)
$4.06M
−0.7% YoY Q2 Aug 2023
Net Income (TTM)
−$84.62M
−14.6% YoY Q2 Aug 2023
EPS Diluted (TTM)
−$0.29
+39.6% YoY Q2 Aug 2023
Gross Margin
—
Q2 Aug 2023
Operating Margin
-2,072.2%
Q2 Aug 2023
Net Margin
-2,084.7%
Q2 Aug 2023
Free Cash Flow (TTM)
−$69.73M
Q2 Aug 2023
Cash
$228.27M
Q2 Aug 2023
Total Debt
—
Q2 Aug 2023
Shares Outstanding
434.07M sh
Q2 Aug 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings